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Abstract
Background—Acyclovir is used to treat herpes infections in preterm and term infants; however,
the influence of maturation on drug disposition and dosing requirements is poorly characterized in
this population.
Methods—We administered intravenous acyclovir to preterm and term infants <31 days
postnatal age and collected plasma samples. We performed a population pharmacokinetic analysis.
The primary pharmacodynamic target was acyclovir concentration ≥3 mg/L for ≥50% of the
dosing interval. The final model was simulated using infant data from a clinical database.
Results—The analysis included 28 infants (median 30 weeks gestation). Acyclovir
pharmacokinetics was described by a 1-compartment model: clearance (L/h/kg) = 0.305 ×
(postmenstrual age [PMA]/31.3 weeks)3.02. This equation predicts a 4.5-fold increase in clearance
from 25 to 41 weeks PMA. With proposed dosing, the pharmacodynamic target was achieved in
91% of infants: 20 mg/kg every 12 hours in infants <30 weeks PMA; 20 mg/kg every 8 hours in
infants 30 to <36 weeks PMA; 20 mg/kg every 6 hours in infants 36–41 weeks PMA.
Conclusions—Acyclovir clearance increased with infant maturation. A dosing strategy based on
PMA accounted for developmental changes in acyclovir disposition to achieve the surrogate
pharmacodynamic target in the majority of infants.
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Intravenous acyclovir is routinely used to treat herpes simplex virus (HSV) infection in
preterm and term infants. Although acyclovir has reduced mortality from neonatal HSV
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infections, neurodevelopmental impairment among survivors remains high.1–3 Persistence of
HSV in the cerebrospinal fluid following completion of intravenous antiviral therapy is an
independent risk factor for worse outcomes,4 suggesting that poorer outcomes may be
related to inadequate antiviral exposure.5
Acyclovir dosing recommendations for infants vary. The Food and Drug Administration
(FDA) label-approved dosing (10 mg/kg every 8 hours) differs from more recent evidence
showing reduced mortality with a higher dose (20 mg/kg every 8 hours), the current standard
of care.2,6 Pediatric dosing handbooks recommend a 20 mg/kg/dose with variable dosing
intervals determined by age stratifications: Redbook and Lexicomp recommend an 8-hour
dosing interval for all infants, whereas the Harriet Lane Handbook and Neofax recommend
dosing intervals stratified by gestational age (GA) and postmenstrual age (PMA),
respectively.7–10 More importantly, pharmacokinetic (PK) trials supporting acyclovir dosing
are limited, especially in preterm infants.
Acyclovir is primarily cleared renally through a combination of glomerular filtration and
tubular secretion. In adults, volume of distribution (V) at steady state is about two thirds of
body weight,11 and linear PK are observed in the range of 0.5–15 mg/kg/dose.11,12 In adults
with normal renal function, acyclovir’s elimination half-life (t1/2) is 3 hours.12 In infants
with normal renal function, elimination t1/2 is approximately 4 hours as reported by 2 studies
that did not report the GA distribution12,13 and 5 hours in a study including preterm infants
(median GA 38 weeks).14 In a cohort of 22 infants <3 months of age with a history of HSV
infection, all HSV isolates had an acyclovir half maximal inhibitory concentration (IC50) of
<1 mg/L.15 Acyclovir levels in cerebrospinal fluid (CSF) are approximately 30–50% of
corresponding plasma levels.12 Dosing designed to maintain plasma concentrations ≥3 mg/L
would be necessary to maintain an acyclovir concentration ≥1 mg/L in the CSF. For safety,
plasma acyclovir concentrations of 50–70 mg/L have been associated with neurotoxicity in a
small subset of patients.16–18
Small sample sizes and infrequent inclusion of preterm infants in prior acyclovir PK studies
prevented the characterization of acyclovir PK in the setting of rapid physiologic maturation.




Two studies contributed the data for this report. Study 1 was a single-center, open-label, PK
study of infants 23–42 weeks GA and <61 days postnatal age (PNA) with suspected
systemic infection. Study 2 was a multi-center, open-label, PK study of infants 23–34 weeks
GA and <45 days PNA with suspected HSV infection. Exclusion criteria included: history of
anaphylaxis attributed to acyclovir; renal dysfunction indicated by serum creatinine (SCR)
>1.7 mg/dL; and urine output <0.5 mL/kg/hour over the previous 12 hours (Study 2 only).
Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in
Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA:
10 mg/kg every 12 hours (23–29 weeks GA and <14 days PNA); 20 mg/kg every 12 hours
(23–29 weeks GA and 14–44 days PNA); and 20 mg/kg every 8 hours (30–34 weeks GA
and <45 days PNA). Clinical data collected included the following: demographics (e.g., GA,
PNA, birth weight, current weight, race, sex, ethnicity), laboratory values collected as part
of routine medical care (SCR, liver function tests, albumin), concomitant medications (other
antimicrobials, vasopressors), and microbiological cultures. The study was approved by
institutional review boards at each site and was conducted in accordance with the Helsinki
Declaration; the legally authorized guardian provided informed consent.
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Blood was collected (100–200 µL) around the first dose, at steady state, and after the last
dose. In Study 1, upon end of the first acyclovir infusion, samples were collected within 5
minutes, at 2–4 hours, and at 6–8 hours. Upon end of infusion at steady state (doses 5–15),
samples were collected within 5 minutes, at 2–4 hours, 6–8 hours, and immediately prior to
the next dose. In Study 2, upon end of the first acyclovir infusion, samples were collected
within 15 minutes and within 30 minutes prior to the second dose. Upon end of infusion at
steady state (doses 5–15), samples were collected within 15 minutes, at 2–3 hours, and
within 30 minutes prior to the next dose. After the end of the last infusion, samples were
collected at 15–18 hours.
Bioanalytical Assay
Plasma samples were analyzed for acyclovir concentrations using an LC/MS/MS
bioanalytical assay validated according to FDA guidance.19 Dicloxacillin was used as the
internal standard. Drug was extracted from plasma using protein precipitation with
acetonitrile. The lower limit of quantitation was 0.1 mg/L. The calibration range was 0.1–50
mg/L. The intra-day and inter-day coefficients of variation in drug concentration
measurements were 14% and 8%, respectively. Samples from both studies were run with the
same bioanalytical assay. Plasma samples were stored up to 22 months prior to analysis.
Population PK Analysis
Data were analyzed using nonlinear mixed effects modeling implemented in NONMEM 7
software (ICON, Ellicott City, MD, USA) using the first-order conditional estimation
method with interaction. One- and 2-compartment structural models and proportional and
proportional plus additive residual error models were explored. Random effects on structural
model parameters were considered supported by the data if shrinkage was <30%. Weight
was included a priori as a covariate for V and clearance (CL) in the base model. Diagnostic
plots included the following: observed concentration versus predicted concentration and
versus individual predicted concentration; weighted residuals and conditional weighted
residuals versus predicted concentration and versus time after dose; conditional weighted
residuals histogram; and observed versus predicted and individual predicted concentrations
by infant. Diagnostic plots and objective function value (OFV) were used to assess goodness
of fit.
Once the base model was identified, covariates were investigated for their influence on PK
parameters (e.g., CL and V). Continuous covariates evaluated were PNA, GA, PMA, and
SCR; categorical covariates included race, ethnicity, sex, and use of concomitant
vasopressin, dopamine, or epinephrine. Missing covariate values were imputed using the
closest value available for that participant using either a carry-forward approach or back-fill
approach depending on which date was closest. If there was a tie in the number of days from
the prior and next available value, then the prior available value was used (i.e., carried
forward). Individual participant ηCLs and ηVs were plotted against covariates to graphically
assess relationships between variability in PK parameters and covariates. Covariates with a
discernible graphical relationship to ηCL and ηV were evaluated for inclusion in the final
model. The threshold for significance of a single covariate was reduction of the objective
function by more than 3.84 (P<0.05). A forward-addition, backward-elimination approach to
covariate selection was planned for use if more than 1 covariate was found to be significant
for CL or V.
Sampson et al. Page 3














The robustness and stability of the final PK model was assessed by nonparametric bootstrap
using WINGS for NONMEM version 7 (Auckland, NZ), where the original data were
resampled, with each individual participant being a sampling unit. One thousand datasets
were generated and fit to the final model to assess precision of the PK parameters and
agreement between final model and bootstrap parameter estimates.
A standardized visual predictive check (VPC) was conducted to compare observed acyclovir
concentrations at each time point as a percentile of 1000 simulated datasets from the final
model.20 One advantage of the standardized VPC is that binning of concentrations into
arbitrary time intervals is unnecessary, and differences in dosing are accounted for as the
data represent percentiles. The threshold for good agreement between simulated and
observed data was <15% of observed concentrations falling outside the 5th to 95th percentile
range.
Dose-exposure Assessment
The surrogate efficacy pharmacodynamic (PD) targets were acyclovir maximum
concentration at steady state (Cmaxss), steady-state plasma concentrations at 50% of the
dosing interval (C50ss), and minimum concentration at steady state (Cminss) ≥3 mg/L and
≥1 mg/L. C50ss was chosen as a conservative, primary surrogate PD target due to the severe
morbidities associated with HSV encephalitis in infants.21 These PD targets were chosen
based on HSV IC50 = 1 mg/L15 and reported acyclovir central nervous system penetration
of approximately 30–50%.12 Based on case report data in children and adults, surrogate
safety targets of Cmaxss <50 mg/L (primary) and <70 mg/L were chosen.16–18 Study dosing
and individual Bayesian estimates of PK parameters for each infant in the study population
were used to calculate PD target attainment. The following equations were used:
Cmaxss=((Dose/tin)/CL) * (1-e(−Ke*tin)) * (1/1-e(−Ke*tau)), where dose (mg) is the
first administered dose, tin is infusion duration (1 hour for both studies), Ke (h−1) is
elimination rate constant, and tau (h) is the dosing interval;
C50ss= Cmaxss * e(−Ke*(tau-tin)*0.5));
Cminss= Cmaxss * e(−Ke*(tau-tin)).
The proportions of infants in the study population meeting the PD and safety targets were
determined.
We used data from a de-identified dataset containing information on infants from more than
300 neonatal intensive care units to simulate acyclovir exposures in a larger population. The
analysis was approved by the Duke University Institutional Review Board without the need
for written informed consent as the data were collected without patient identifiers.22,23 The
ranges of GA, PNA, PMA, and SCR (see Table 1) in our study population were used to
identify infants for our simulations. Infants lacking a blood culture or exposure to antibiotic
therapy were excluded. A random sample of 1000 infants, from the remaining dataset, was
included in the simulations. The proportions of infants meeting the PD and safety targets
were determined.
Safety
The safety cohort consisted of infants who received ≥1 dose of study medication. All
adverse events (AEs) were recorded from the time of first study drug administration through
3 days following the last dose of study drug. All suspected AEs and serious AEs (SAEs)
were recorded from time of first study drug administration through 10 days following the
last study drug administration.
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Study Population and PK Specimens
Ninety-two plasma samples from 30 infants were obtained. Nine (9.8%) samples were
suspected to be drawn during infusion or flush and were excluded prior to model
development. The final model was used to screen for extreme outlier concentrations (>10-
fold difference from predicted concentration), suggesting sample contamination or other
collection or dosing error. Two additional (2.2%) samples were identified as outliers and
excluded after identification of the final model. This resulted in exclusion of 2 participants
(each with 1 plasma sample). The final dataset included 81 samples from 28 infants with
relatively normal renal function: 36 samples from 12 infants in Study 1 and 45 samples from
16 infants in Study 2. The median (range) number of samples per infant regardless of GA at
birth (<34 vs. ≥34 weeks) was 3 samples (1–5). The critically ill status of the infants and
timing of PK samples with standard-of-care laboratory tests prevented the collection of all
planned timed samples. Demographics at the time of first PK sample are shown in Table 1.
The median (range) duration of drug administration was 1.0 hour (0.4–1.2), and the median
acyclovir concentration was 5.8 mg/L (0.7–110).
Population PK Model Building
A 1-compartment base model was selected, as a 2-compartment model did not significantly
improve goodness of fit. A proportional residual error model was selected over a
proportional plus additive model because the latter did not improve goodness of fit. As a
plot of individual participant deviations from the typical population PK parameter values (η)
for CL and V suggested correlation, covariance between these parameters was estimated.
Random effects were supported on CL and V with shrinkage <6%. Covariate models for
weight were explored with an estimated or fixed (3/4 or 1) exponent; an exponent of 1 was
included in the base model.
Plots of PMA, PNA, GA, and SCR were suggestive of a relationship with ηCL; no
covariates were suggestive of a relationship with ηV other than weight. PMA was identified
as the most significant age covariate for acyclovir CL. SCR was the only significant non-age
covariate during the univariate analysis for CL. Addition of SCR to the PMA model did not
significantly reduce the OFV. Thus the final model includes weight and PMA as covariates
for CL and weight as the covariate for V. The final model predicts a 4.5-fold increase in CL
(and a 4.5-fold decrease in t1/2) from 25 to 41 weeks PMA. Covariate models for weight
were again explored with an estimated or fixed (3/4 or 1) exponent in the final model.
Compared with an exponent of 1, the OFV decreased by 9.38 for an estimated exponent
(1.46) and increased by 7.74 for an exponent of 3/4. An exponent of 1 was included in the
final model. Final model diagnostic plots show minimal bias in observed vs. predicted
concentrations or in residuals (Figure 1). Significant model-building steps are shown in
Table 2.
Population PK Model Evaluation
Of 1000 final model bootstrap runs, 98.8% converged. All bootstrap runs were included in
the analysis. The final model had a high level of precision between all final model and
bootstrap parameter estimates with differences of <7.2% (Table 3). The standardized VPC
indicated good agreement between observed and model-simulated concentrations, with 7.4%
(6/81) of observations outside the 90% prediction interval. Observations were approximately
symmetric about the 50th percentile line (Figure 2).
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Individual Bayesian PK Parameter Estimates
The median empirical Bayesian post-hoc parameter estimate for CL, 0.278 L/hr/kg, was
within 10% of the typical population model estimate of 0.305 L/hr/kg. Comparing the
youngest and oldest PMA cohorts, CL estimates increased 2.8-fold, V estimates were
unchanged, and t1/2 estimates decreased 3.4-fold (Table 4 and Figure 3).
Dose-exposure Assessment
Using the dosing infants received in the 2 trials, 28/28 infants (100%) had C50ss ≥3 mg/L.
Cminss was ≥3 mg/L for 18/28 (64%) infants: 7/12 (58%) in Study 1 and 11/16 (69%) in
Study 2. All (28/28) infants had steady-state concentrations ≥2 mg/L (twice the secondary
PD target of 1 mg/L) throughout the dosing interval. Three out of 28 (11%) infants had
Cmaxss ≥50 mg/L; these infants were in Study 1 and received doses of 31–53 mg/kg every 8
hours.
Based on the final PK model, a PMA-based dosing regimen was developed to account for
developmental changes in acyclovir disposition in infants with relatively normal renal
function: 20 mg/kg every 12 hours in infants <30 weeks PMA; 20 mg/kg every 8 hours in
infants 30 to <36 weeks PMA; and 20 mg/kg every 6 hours in infants 36–41 weeks PMA.
The final PK model and proposed dosing regimens were used to predict acyclovir
concentrations in 1000 randomly selected infants from a clinical care database. The PMA-
based dosing regimen predicted 91% and 100% of infants would have C50ss ≥3 mg/L and
≥1 mg/L, respectively. Predicted Cmaxss safety thresholds of 50 and 70 mg/L were exceeded
by 0.9% and 0.3% of infants, respectively. The PMA-based dosing regimen was superior to
regimens found in commonly used pediatric dosing sources, including the FDA label. None
of the earlier dosing regimens consistently achieved the PD target of C50ss ≥3 mg/L for
≥90% of infants (Table 5). Due to high correlation between ηCL and ηV and higher-than-
expected inter-individual variability in V observed in the final model, simulations were also
performed without inter-individual variability on V and showed similar results (data not
shown).
Safety
Acyclovir was well tolerated. The safety cohort included 32 infants. This critically ill cohort
had a history of the following conditions at baseline: respiratory, thoracic, and mediastinal
disorders (78%); nervous system disorders (37%); and metabolic acidosis (19%). None of
the evaluations for HSV (surface cultures [n=19], CSF polymerase chain reaction [PCR]
[n=7]) were positive. Overall, 38 AEs were reported in 66% of the participants. Infants <14
days PNA and 23–29 weeks GA had the highest proportion of AEs (90%). Only 1 AE was
considered related to study drug (worsening SCR), and study drug was discontinued in this
participant. A total of 4 SAEs were reported in 4 infants (13%). Two of the SAEs were
infant deaths: 1 due to nonketotic hyperglycinaemia and 1 due to sepsis. The other 2 SAEs
were neuroblastoma and neonatal asphyxia. No SAEs were determined to be related to study
drug. No episodes of neutropenia were reported as AEs. Fifteen infants (47%) received >80
mg/kg/day of acyclovir (range 87–158). Infants with SAEs received 75–103 mg/kg/day. One
of 4 infants with SAEs had a predicted Cmaxss >50 mg/L.
DISCUSSION
This study evaluated the population PK of acyclovir in 28 preterm and term infants. A 1-
compartment model appropriately described the data and was precise as evidenced by
population CL and V point estimates nearly identical to the median bootstrap values and
narrow 95% confidence intervals. A maturational change in acyclovir CL was included in
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the final model through the PMA covariate. From 25–41 weeks PMA, the final model
predicts a large (4.5-fold) increase in CL, and equivalent decrease in t1/2.
This association was expected as acyclovir is primarily renally eliminated, and renal
function rapidly develops with both advancing GA and PNA during the first months of
life.14,24 GA and PNA can vary considerably for a given value of PMA; however, the
sample size of this study likely precluded identification of separate covariate effects of GA
and PNA on CL. SCR was also a significant covariate (though with smaller effect than
PMA), consistent with a prior study in 16 infants of median (range) 38 (27–40) weeks GA.14
This study was limited to infants with relatively normal renal function; a study of infants
with renal dysfunction would likely result in a stronger association between acyclovir
clearance and SCR. While creatinine clearance is a good measure of renal function in adults,
methods for calculating creatinine clearance in infants are sub-optimal, and we relied only
on SCR for PK/PD modeling. There were no apparent age-related effects on acyclovir V;
however, the ability to detect such a relationship may have been limited by the small sample
size.
The acyclovir population CL estimates in the present study were similar to estimates
reported in another population that included premature infants (typical CL 0.265 L/kg/h for
an infant 38 weeks GA).14 The median (range) V Bayesian estimates were 3.34 (0.29–
10.85) L/kg, which is larger than values previously reported in adults (0.7 L/kg)12 and in a
study of 16 infants up to 3 months PNA (median [range] 1.0 [0.4–6.5] L/kg).13 The
differences in V in this study could be related to higher content of total body water and the
critical condition of these infants.25
Inter-individual variability estimates for CL (52.8%) and V (85.0%) were larger than
expected. For example, in a study of intravenous ganciclovir in 27 infants, inter-individual
variability estimates for CL and V were 35% and 30%, respectively.26 In another study of
intravenous ganciclovir and oral valganciclovir in 24 infants, the estimated inter-individual
variability CL was 28%.27 A study of 9 infants (4 term and 5 preterm) found acyclovir
levels varied widely among infants receiving the same dose but were correlated with the
expected renal maturity of the individual infant.28 However, it is possible that the large
variability observed is an accurate reflection of variability in acyclovir disposition in
preterm and term infants. In spite of this variability, however, the proposed dosing regimen
achieved pre-specified surrogate efficacy targets.
Simulations of our proposed dosing regimens, compared with prior studies in adults and
infants, predict more variable peak concentrations and overlapping trough concentrations. At
doses of 15 mg/kg every 8 hours, reported Cmaxss in 2 adults and 4 infants was mean ±
standard deviation 23 ± 0.2 mg/L and median (range) 22.7 (16.2–33.7) mg/L, respectively;
Cminss was 2.0 ± 0.1 mg/L and 4.4 (1.5–23.9) mg/L, respectively.12,28 Simulations of our
proposed dosing regimen in infants with PMA 36–41 weeks predicts median (range) Cmaxss
of 9.0 (1.3–79.6) mg/L and Cminss of 3.3 (0.8–9.7) mg/L.
Validated PD targets for acyclovir are lacking. In the absence of such targets, surrogate
efficacy is often assessed by comparison of in vivo acyclovir concentrations to in vitro IC50
values for HSV clinical isolates. C50ss was chosen as a primary target in this study as a
balance between a stringent target such as Cminss, while being more conservative than
Cmaxss.
Any acyclovir efficacy target must account for CSF penetration. A post-treatment reservoir
of HSV in the central nervous system would increase the risk of recurrence and its attendant
risks of poor neurodevelopmental outcomes for infants.29 However, data relating CSF HSV
PCR status to acyclovir CSF concentrations pre- and post-treatment are minimal in adults
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and lacking in premature and term infants. In a study of nine adults with positive CSF HSV
PCR at time of enrollment treated with 21 days of 1000 mg oral valacyclovir (acyclovir
prodrug) three times daily, serial CSF HSV PCR measures on days 2, 10, and 20 were
obtained. Four patients completed treatment and had a negative CSF HSV PCR status by
day 10. The mean ± standard deviation of CSF concentrations collected from all patients
peaked on day 2 at 1.46 ± 1.01 mg/L and were at a minimum (and nearly identical) on days
0 and 20 (∼0.8 ± 0.38 mg/L). Assuming similar CSF penetration in premature and term
infants compared to adults, these data are supportive of our choice of 1 mg/L as an effective
acyclovir concentration in CSF.30 Future studies are needed in infants to identify the
acyclovir exposure metrics in plasma, CSF, and other target organs that maximize efficacy.
Acyclovir concentrations associated with toxicity are not well defined in any age group. AEs
reported with acyclovir include renal dysfunction, injection site reactions, seizures, and rare
leucopenia and thrombocytopenia. Following acyclovir treatment for viral mucocutaneous
infection or pneumonia, plasma acyclovir concentrations of 50–70 mg/L have been
associated with toxicity in a small subset of patients.16–18 Although 3/28 (10.7%) infants in
the study population exceeded Cmaxss ≥50 mg/L with trial doses of 30–50 mg/kg every 8
hours, simulations in 1000 infants predict <1% of infants would exceed this safety target
with the proposed dosing scheme.
We recommend a higher acyclovir dose (20 mg/kg every 6 hours) for infants 36–41 weeks
PMA than has been prospectively shown to be safe.2 Fifteen infants in our study received
>80 mg/kg/day of acyclovir dosed every 8 hours, and none had SAEs attributed to acyclovir.
The adverse effects most commonly associated with acyclovir are neutropenia and
nephrotoxicity. Neutropenia can be easily detected by laboratory monitoring, and acyclovir
dosing modifications in the setting of renal dysfunction are available. Considering the risk of
death and long-term neurodevelopmental impairment associated with HSV infection, we
think the risk-to-benefit ratio favors aggressive acyclovir dosing to ensure adequate
exposure.
Acyclovir dosing for infants is improved, optimized, and simplified by this study. Of the 2
trials comprising this dataset, Study 1 used body surface area dosing unstratified by age, and
Study 2 used 3 different weight-based dose levels in 3 age strata based on GA and PNA. Our
proposed weight-based dosing regimen simplifies dosing to include only PMA. In addition,
the use of real infant information from a clinical care database for simulations increases the
likelihood that our simulation results will match results in clinical practice because the
demographic distribution arises from infants with presumed systemic infections. Our
proposed dosing achieves plasma acyclovir C50ss ≥3 mg/L in >90% of infants and
outperforms dosing regimens found in current pediatric dosing handbooks. Our proposed
dosing is consistent with a study of 66 infants (mean GA 38 weeks and 33% premature) with
HSV that observed improved survival with a dose of 60 mg/kg/day vs. 30 mg/kg/day.2
The population PK of acyclovir in infants shows that PMA is associated with CL. A dosing
strategy based on PMA was developed to account for developmental changes in acyclovir
disposition in infants with relatively normal renal function: 20 mg/kg every 12 hours in
infants <30 weeks PMA, 20 mg/kg every 8 hours in infants 30 to <36 weeks PMA, and 20
mg/kg every 6 hours in infants 36–41 weeks PMA. This dosing strategy achieved the
surrogate PD target in the majority of infants.
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Final population PK model diagnostic plots. (A) Observed vs. population predictions; (B)
observed vs. individual predictions; (C) conditional weighted residuals vs. population
predictions; (D) conditional weighted residuals vs. time since first dose. A locally weighted
scatterplot smoothing line was fit to the data points in C and D.
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Standardized visual predictive check. Solid black circles: observed concentrations; dashed
black lines: 5th, 50th, and 95th percentiles of predicted concentration.
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Relationship between individual Bayesian PK parameter estimates and PMA. (A) Clearance;
(B) half-life.
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TABLE 1
Participant Demographics (n=28)
N (%) or median (range)
Gestational age (weeks) 30 (23–40)
Postnatal age (days) 3 (1–30)
Postmenstrual age (weeks) 31 (25–41)
Birth weight (g) 1295 (510–4840)
Weight (g) 1370 (578–5720)
Female 15 (54)
White 16 (57)
Serum creatinine (mg/dL) 0.9 (0.3–1.8)
Vasopressin use 1 (4)
Dopamine use 4 (14)
Epinephrine use 7 (25)
Values for PNA, PMA, and weight are at the time of first PK sample collection. Concomitant medication use refers to any time during the study.
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TABLE 2
Summary of Steps in the Acyclovir Model-building Process
Description Population model OFV ΔOFV
V (all models) V(L/kg)=2.8 1500.7 -
CL base model CL(L/h/kg)=0.299 1500.7 -
PNA on CL CL(L/h/kg)=0.319*(PNA/3.5)−0.161 1498.0 −2.7
SCR on CL CL(L/h/kg)=0.275*(0.9/SCR)0.577 1492.0 −8.7
GA on CL CL(L/h/kg)=0.295*(GA/30.5)2.35 1481.7 −19.0
PMA on CL CL(L/h/kg)=0.280*(PMA/31.3)3.00 1478.9 −21.8
GA, PNA, and SCR on CL CL(L/h/kg)=0.283*(PNA/3.5)−0.007 *(0.9/SCRE)0.441*(GA/30.5)2.16 1476.2 −24.5
PMA and SCR on CL CL(L/h/kg)=0.269*(0.9/SCR)0.577 *(PMA/31.3)3.02 1475.3 −25.4
PMA on CL (2 outliers dropped) CL(L/h/kg)=0.305*(PMA/31.3)3.02 1408.5 −92.2
Two outliers (observed concentration >10X different from the predicted concentration) dropped in the final model. ?OFV is relative to the base
model.
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